Literature DB >> 21826471

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Riccardo Caccialanza1, Giovanni Palladini, Catherine Klersy, Emanuele Cereda, Chiara Bonardi, Barbara Cameletti, Elisabetta Montagna, Paola Russo, Andrea Foli, Paolo Milani, Francesca Lavatelli, Giampaolo Merlini.   

Abstract

Nutritional status is an independent prognostic factor in immunoglobulin light-chain amyloidosis (AL), but its influence on quality of life (QoL) is unknown. The aim of this cross-sectional study was to investigate the association between nutritional status and QoL in AL patients at diagnosis. One hundred and fifty consecutive patients with biopsy-proven AL were assessed for nutritional status by anthropometry [body mass index, unintentional weight loss (WL) in the previous 6 months and mid-arm muscle circumference (MAMC)], biochemistry (serum prealbumin), and semiquantitative food intake at referral. QoL was assessed by the Medical Outcomes Study 36-item Short Form General Health Survey. The composite physical component summary (PCS) and the mental component summary (MCS) for AL outpatients were 36.2 ± 10.1 and 44.9 ± 11.3, respectively (p < 0.001 for both vs the population norms of 50). In multivariate linear regression models adjusted for gender, age, Eastern Cooperative Oncology Group performance status, the number of organs involved, the severity of cardiac damage, C-reactive protein, energy intake, and WL, PCS was significantly lower for serum prealbumin <200 mg/L and MAMC <10th percentile (adjusted difference 3.8, 95% CI 0.18-7.5, p = 0.040 and 5.3, 95% CI 2.0-8.7, p = 0.002, respectively). MCS was decreased by 0.47 (95% CI 0.18-0.75, p = 0.002) for each kilogram of body weight lost in the previous 6 months. Nutritional status independently affects QoL in AL patients since diagnosis. Nutritional evaluation should be integral part of the clinical assessment of AL patients. Nutritional support intervention trials are warranted in such patients' population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826471     DOI: 10.1007/s00277-011-1309-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

2.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

3.  A prospective study of nutritional status in immunoglobulin light chain amyloidosis.

Authors:  Prayman T Sattianayagam; Thirusha Lane; Zoe Fox; Aviva Petrie; Simon D J Gibbs; Jennifer H Pinney; Signe S Risom; Dorota M Rowczenio; Ashutosh D Wechalekar; Helen J Lachmann; Janet A Gilbertson; Philip N Hawkins; Julian D Gillmore
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

4.  The burden of amyloid light chain amyloidosis on health-related quality of life.

Authors:  Martha Bayliss; Kristen L McCausland; Spencer D Guthrie; Michelle K White
Journal:  Orphanet J Rare Dis       Date:  2017-01-19       Impact factor: 4.123

5.  Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples.

Authors:  Michelle K White; Kristen L McCausland; Vaishali Sanchorawala; Spencer D Guthrie; Martha S Bayliss
Journal:  Patient Relat Outcome Meas       Date:  2017-12-07

Review 6.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

Review 7.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

8.  Content validation of the SF-36v2® health survey with AL amyloidosis patients.

Authors:  Michelle K White; Martha S Bayliss; Spencer D Guthrie; Kimberly P Raymond; Avery A Rizio; Kristen L McCausland
Journal:  J Patient Rep Outcomes       Date:  2017-12-08

9.  A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.

Authors:  Vaishali Sanchorawala; Kristen L McCausland; Michelle K White; Martha S Bayliss; Spencer D Guthrie; Stephen Lo; Martha Skinner
Journal:  Br J Haematol       Date:  2017-08-29       Impact factor: 6.998

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.